Axonics® Announces Closing of Initial Public Offering of Common Stock
Axonics’ common stock began trading on The Nasdaq Global Select Market
under the ticker symbol “AXNX” on
BofA Merrill Lynch and
A registration statement on Form S-1, including a prospectus relating to
the offering, has been filed with, and declared effective by, the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Axonics has developed an innovative rechargeable SNM system for the
treatment of patients with OAB, FI, and UR. Axonics’ proprietary r-SNM
System is designed to be 60% smaller than existing technology and to
last approximately 15 years. Axonics currently has marketing approvals
Axonics Modulation Technologies, Inc.
Dan Dearen, +1-949-396-6320
President & Chief Financial Officer
Investor & Media Contact
Matt Clawson, +1-949-370-8500